NeOnc Technologies (NTHI)
Develops intranasal NEO100 and oral NEO212 candidates for brain tumors.
NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger
DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent brain cancer. After its latest Phase 2a readout, the bigger move is whether those results can support a credible path toward registration.
NeOnc's Clinical Story Is Now the Main Event
DENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens if NEO100's clinical results translate into a viable regulatory pathway for a difficult-to-treat form of brain cancer? On August 12, NeOnc reported positive topline Phase 2a results from its NEO100-01 study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't
DENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has just added another potentially important element to an already potent story: its CEO, Amir Heshmatpour, is continuing to buy shares on the open market. According to the Form 4 transaction information provided by the company's latest filing, Heshmatpour purchased 12,000 NTHI shares on August 14 at an average price of $3.7883 and another 3,000 shares on August 17 at an average price of $4.3733.
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NeOnc's (NASDAQ:NTHI) Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma make its Nasdaq Global Market listing way more interesting
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).
The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings' (NASDAQ: NTHI) August 12 headline was impossible to miss, but another interesting solution may be hiding in plain sight: while NeOnc produced encouraging data for one cancer drug, it also generated human clinical evidence around a non-invasive intranasal delivery strategy designed to reach the brain without relying on conventional systemic delivery across the blood-brain barrier. NeOnc's own filings describe NEO100 as an intranasally administered formulation of purified perillyl alcohol and identify intranasal delivery as one of several approaches the company is investigating to overcome the blood-brain barrier.
Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: its Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care, producing a reported p-value of 0.0047. The company also reported median overall survival of 26.09 months, with 86.7% of patients alive at six months, 60.9% at 12 months and 54.1% at 24 months.
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high impact catalyst day with what market observers are describing as a classic triple confluence setup. The company will release topline Phase 2a results for its intranasal NEO100 therapy in recurrent IDH1-mutant high-grade glioma, a difficult-to-treat form of brain cancer on Wednesday, August 12 at 8:30 a.m.
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced the appointment of Nasim Shomali to its Board of Directors, effective July 1, 2026.
NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum
DENVER, June 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is entering one of the most significant periods in its corporate history after securing its second Investigational New Drug (IND) authorization from the United Arab Emirates this month, further expanding international development opportunities for its central nervous system cancer pipeline. The latest authorization from the Department of Health – Abu Dhabi grants IND status to NEO100, NeOnc's lead intranasal therapy candidate for recurrent high-grade gliomas.
Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND
DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) – NeOnc Technologies Holdings (NASDAQ: NTHI) continues to build momentum as a neuro-oncology sector trailblazer, as it advances multiple clinical programs targeting some of the most difficult cancers to treat, after announcing that the Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, the company's oral perillyl alcohol-temozolomide conjugate being developed for aggressive brain tumors. The approval represents the first international regulatory clearance for NEO212 following completion of the Phase 1 dose-escalation study, which established 610 mg as the recommended Phase 2 dose.
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates
New Funding Structure Includes Redemption Rights, Ownership Limitations, and Conversion Floor as Investors Monitor Upcoming Clinical Updates Houston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) continues to attract attention within the biotechnology sector as the Company advances its neuro-oncology pipeline and strengthens its balance sheet ahead of anticipated clinical development milestones. NeOnc's new Securities Purchase Agreement with accredited investors provides for up to $5 million through the issuance of Series A Convertible Preferred Stock.
The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade
NeOnc Technologies Advances Novel Neuro-Oncology Therapies Targeting Glioblastoma and Other Hard-to-Treat Brain Cancers Houston, Texas--(Newsfile Corp. - June 9, 2026) - For years, artificial intelligence has dominated conversations surrounding the future of healthcare innovation. Yet beyond the AI-driven headlines, another potentially groundbreaking revolution is unfolding in one of medicine's most challenging arenas: the fight against brain cancer.
The Next Great AI Revolution May Be Drug Delivery
DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (www. 247marketnews. com) - When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most important long-term applications of AI may ultimately emerge inside healthcare, particularly in the development and delivery of advanced therapeutics.
The Next Great AI Revolution May Be Drug Delivery
NeOnc (NASDAQ:NTHI) is developing therapies and delivery technologies targeting aggressive brain cancers and CNS-related conditions, and could be part of t
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) – NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies. Maxim Group and Alliance Global Partners initiated coverage on NeOnc with a favorable ratings and targets, highlighting what the firms see as significant benefit potential relative to the company's current market position.
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones.
Biotech's Next Wave May Already be in Motion
DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape.
Where Executives Are Doubling Down on Their Companies’ Fortunes
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money to work. Executives and strategic stakeholders have been accumulating shares in meaningful size, ranging from six-figure buys to billion-dollar commitments.
Where Executives Are Doubling Down on Their Companies' Fortunes
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money to work. Executives and strategic stakeholders have been accumulating shares in meaningful size, ranging from six-figure buys to billion-dollar commitments.